Response to letter entitled: ‘Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors’

Heinzerling L, La Rosée P, Gutzmer R, Kramer R, Keller-Stanislawski B, Zierold S, Mentzer D (2021)

Publication Type: Journal article

Publication year: 2021

Journal

European Journal of Cancer Elsevier

Book Volume: 153

Pages Range: 272-273

DOI: 10.1016/j.ejca.2021.05.028

Authors with CRIS profile

Rafaela Kramer Department of Dermatology

Involved external institutions

Klinikum der Universität München DE Germany (DE) Schwarzwald-Baar Klinikum DE Germany (DE) Ruhr-Universität Bochum (RUB) DE Germany (DE) Paul Ehrlich Institute / Paul-Ehrlich-Institut – Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (PEI) DE Germany (DE)

How to cite

APA:

Heinzerling, L., La Rosée, P., Gutzmer, R., Kramer, R., Keller-Stanislawski, B., Zierold, S., & Mentzer, D. (2021). Response to letter entitled: ‘Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors’. European Journal of Cancer, 153, 272-273. https://doi.org/10.1016/j.ejca.2021.05.028

MLA:

Heinzerling, Lucie, et al. "Response to letter entitled: ‘Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors’." European Journal of Cancer 153 (2021): 272-273.

BibTeX: Download